InvenireX builds a DNA nanotechnology platform to detect disease at early biological stages.
Newcastle-based InvenireX has developed a DNA nanotechnology platform designed to detect early-stage disease markers. The technology utilises programmable structures and artificial intelligence to identify molecular targets with high sensitivity.
Net current assets
Total assets less current liabilities
Net assets
Shareholders' funds
Fixed assets
Current assets
Cash, assets and headcount from InvenireX's latest Companies House filing — with year-on-year movement, free with a Winfred account.
Daniel Todd
Founder
Daniel is the founder and chief executive of InvenireX, alongside roles as a scientist and researcher. He brings academic and scientific experience from Newcastle University and ICOS.
LinkedIn
Dan Todd
CEO and founder
Dan brings deep tech experience in DNA nanotechnology, artificial intelligence, and hardware. He currently serves as founder and CEO of InvenireX, alongside roles as a scientist and PhD researcher at Newcastle University.
The funding round was led by DSW Ventures with participation from XTX Ventures, Cambridge Technology Capital, angel investors, and Innovate UK.
DSW Ventures and XTX Ventures backed the pre-seed round, which will fund prototype optimisation and technical validation.
